SEC Form SC 13D/A filed by ADC Therapeutics SA (Amendment)

SEC Form SC 13D/A filed by ADC Therapeutics SA (Amendment)

Recent Analyst Ratings for $ADCT

$ADCT Insider Purchases

$ADCT SEC Filings

$ADCT Insider Trading

$ADCT Analyst Ratings

$ADCT Financials

$ADCT Press Releases

$ADCT Market Insights

$ADCT FDA approvals

$ADCT Leadership Updates

$ADCT Large Ownership Changes

Recent Analyst Ratings for
$ADCT

$ADCT
Insider Purchases

$ADCT
SEC Filings

$ADCT
Insider Trading

$ADCT
Analyst Ratings

$ADCT
Financials

$ADCT
Press Releases

$ADCT
Market Insights

$ADCT
FDA approvals

$ADCT
Leadership Updates

$ADCT
Large Ownership Changes

Chat with this insight

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

SEC Form DEFA14A filed by ADC Therapeutics SA

SEC Form DEF 14A filed by ADC Therapeutics SA

SEC Form PRE 14A filed by ADC Therapeutics SA

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

Director Azelby Robert sold $20,216 worth of shares (6,995 units at $2.89), decreasing direct ownership by 12% to 53,005 units (SEC Form 4)

Director Bizzari Jean-Pierre sold $20,216 worth of shares (6,995 units at $2.89), decreasing direct ownership by 8% to 79,502 units (SEC Form 4)

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on ADC Therapeutics

Guggenheim initiated coverage on ADC Therapeutics with a new price target

ADC Therapeutics upgraded by JP Morgan

Live finance-specific insights

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024

Fastest customizable press release news feed in the world

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Live Market Insights

Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ADC Therapeutics Is Set To Join The Russell 2000 Index And The Broad-market Russell 3000 Index After The 2024 Russell Us Indexes Annual Reconstitution, Effective At The Open Of US Equity Markets On Monday, July 1, 2024

Cantor Fitzgerald Initiates Coverage On ADC Therapeutics with Overweight Rating

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

Live Leadership Updates

This live feed shows all institutional transactions in real time.

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

SEC Form SC 13G filed by ADC Therapeutics SA

SEC Form SC 13D/A filed by ADC Therapeutics SA (Amendment)

SEC Form SC 13G/A filed by ADC Therapeutics SA (Amendment)

4/28/23 4:08:00 PM ET

$ADCT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADCT alert in real time by email

SC 13D/A 1 d466545dsc13da.htm SC 13D/A SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)*

ADC Therapeutics SA

(Name of Issuer)

Common Shares, par value CHF 0.08 per share

(Title and Class of Securities)

H0036K147

(CUSIP Number)

Stephen Evans-Freke

Auven Therapeutics Holdings L.P.

171 Main Street

Road Town

Tortola

British Virgin Islands VG1110

(340) 779-6908

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 27, 2023

(Date of Event Which Requires Filing of Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON A.T. Holdings II Sarl
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland

(1)	Based on 80,642,527 common shares of ADC Therapeutics SA (the “Issuer”) outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON C.T. Phinco Sarl
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Luxembourg

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON ADC Products Switzerland Sarl
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON Auven Therapeutics Holdings L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON Auven Therapeutics General L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON Auven Therapeutics GP Ltd.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON Stephen Evans-Freke
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION Ireland

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

Schedule 13D

CUSIP No. H0036K147


1		NAME OF REPORTING PERSON Peter B. Corr
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION USA

(1)	Based on 80,642,527 common shares of the Issuer outstanding as of December 31, 2022, as reported in the Issuer’s Form 20-F filed with the SEC on March 15, 2023.

AMENDMENT NO. 6 TO SCHEDULE 13D

The following constitutes Amendment No. 6 (“Amendment No. 6”) to the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) by A.T. Holdings II Sàrl (“A.T. Holdings II”), C.T. Phinco Sàrl (“C.T. Phinco”), ADC Products Switzerland Sàrl (“ADC Products”), Auven Therapeutics Holdings L.P. (“Auven Therapeutics”), Auven Therapeutics General L.P. (“Auven Therapeutics General”), Auven Therapeutics GP Ltd. (“Auven Therapeutics GP”), Stephen Evans-Freke and Peter B. Corr (collectively, the “Reporting Persons”) on May 29, 2020, as amended by Amendment No. 1 filed on October 13, 2020, Amendment No. 2 filed on December 8, 2022, Amendment No. 3 filed on December 9, 2022, Amendment No. 4 filed on December 23, 2022, and Amendment No. 5 filed on February 6, 2023. This Amendment No. 6 amends and supplements the Schedule 13D as specifically set forth herein.

All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

ITEM 4.

PURPOSE OF TRANSACTION

Item 4 of Schedule 13D is supplemented and superseded, as the case may be, as follows:

The disclosure in Item 6 is incorporated herein by reference.

ITEM 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

Item 6 of Schedule 13D is supplemented and superseded, as the case may be, as follows:

Sixth Amendment to Credit and Security Agreement

As previously disclosed, A.T. Holdings II is a borrower under the Credit and Security Agreement and has pledged to the lenders party thereto all of the Common Shares beneficially owned by it or afterward acquired by it to secure the lending by such lenders to A.T. Holdings II pursuant to the Credit and Security Agreement. On April 27, 2023, A.T. Holdings II, as Borrower, C.T. Phinco, as Holdings, the Agent, and the lenders party thereto entered into a Sixth Amendment to the Credit and Security Agreement (the “Sixth Amendment”).

The Sixth Amendment, among other things, provides that C.T. Phinco joins the Credit and Security Agreement as a guarantor and pledges its shares of A.T. Holdings II to secure the Credit and Security Agreement. Furthermore, the Sixth Amendment (i) extends the maturity date to April 15, 2024, (ii) sets the interest rate at (a) 20.00% per annum from February 6, 2023 through September 30, 2023 and (b) 22.5% per annum on and after October 1, 2023, (iii) provides that scheduled interest shall be payable in kind, and (iv) requires that, subject to certain exceptions, cash proceeds from the sale of equity interests be used to repay the obligations under the Credit and Security Agreement. Following A.T. Holdings’ partial repayment of its obligations under the Credit and Security Agreement using proceeds from the Registered Sale, the outstanding principal balance owed under the Credit and Security Agreement was $18,679,772.44 as of the effective date of the Sixth Amendment. The effectiveness of the Sixth Amendment was dependent on the simultaneous execution of the Share Transfer Agreement (as defined below).

Share Transfer Agreement

On April 27, 2023, A.T. Holdings II entered into a Share Transfer Agreement (the “Share Transfer Agreement”) with each lender party thereto (collectively, the “Lenders”) and Oaktree Fund Administration, LLC, as administrative agent on behalf of the lenders (the “Agent”). Pursuant to the Share Transfer Agreement, as soon as reasonably practicable after the payment in full of all obligations under the Credit and Security Agreement, and in any event within five business days following such payment, A.T. Holdings II shall irrevocably transfer, convey, assign and deliver an aggregate of 1,435,749 Common Shares (the “ADCT Shares”) of the Issuer, free and clear of all liens, to the Lenders, which ADCT Shares shall be allocated among the Lenders pro rata in accordance with the principal amount of credit extensions outstanding under the Credit and Security Agreement. The Share Transfer Agreement provides that notwithstanding the foregoing, if, at the earlier of (i) the maturity date of the Credit and Security Agreement or (ii) the acceleration of the obligations under the Credit and Security Agreement, (a) the Agent determines in its sole discretion that A.T. Holdings II does not have sufficient monetizable assets (other than the ADCT Shares) to repay in full all obligations under the Credit and Security Agreement and (b) A.T. Holdings II and the Lenders agree on compensation to the Lenders for allowing the sale of the ADCT Shares, then, following the sale of all other shares of the Issuer that constitute collateral under the Credit and Security Agreement and upon such determination, A.T. Holdings II shall have the right to sell all or a portion of the ADCT Shares and use the proceeds from such sale to pay in full all obligations under the Credit and Security Agreement; provided that any excess cash from such sales is the property of the Lenders.

The foregoing description of the Share Transfer Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Share Transfer Agreement, which is filed as Exhibit 99.1 and is incorporated herein by reference.

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS


Exhibit		Description

99.1		Share Transfer Agreement, dated April 27, 2023, by and between A.T. Holdings II Sàrl, each lender party thereto, and Oaktree Fund Administration, LLC, as administrative agent on behalf of the lenders.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated as of April 28, 2023


A.T. HOLDINGS II SÁRL

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Managing Director

By:		/s/ Peter B. Corr
Name:		Peter B. Corr
Title:		Managing Director

C.T. PHINCO SÁRL

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Class A Manager

By:		/s/ Luis Tavares
Name:		Luis Tavares
Title:		Class B Manager

ADC PRODUCTS SWITZERLAND SÁRL

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Managing Director

By:		/s/ Peter B. Corr
Name:		Peter B. Corr
Title:		Managing Director

AUVEN THERAPEUTICS HOLDINGS L.P.

By:		Auven Therapeutics General L.P., its general partner

By:		Auven Therapeutics GP Ltd., its general partner

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Director


AUVEN THERAPEUTICS GENERAL L.P.

By:		Auven Therapeutics GP Ltd., its general partner

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Director

AUVEN THERAPEUTICS GP LTD.

By:		/s/ Stephen Evans-Freke
Name:		Stephen Evans-Freke
Title:		Director

By:		/s/ Stephen Evans-Freke

By:		/s/ Peter B. Corr

Get the next $ADCT alert in real time by email

Date	Price Target	Rating	Analyst
5/30/2024		Overweight	Cantor Fitzgerald
3/28/2024	$11.00	Buy	Guggenheim
8/10/2023		Underweight → Neutral	JP Morgan
4/24/2023	$7.00 → $2.00	Neutral → Underperform	BofA Securities
12/6/2022	$12.00	Overweight	CapitalOne
11/9/2022	$14.00 → $7.00	Buy → Neutral	BofA Securities
9/21/2022	$5.00	Overweight	JP Morgan
9/9/2022	$17.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

SOLE VOTING POWER

0

SHARED VOTING POWER

6,330,548

SOLE DISPOSITIVE POWER

0

SHARED DISPOSITIVE POWER

6,330,548